Previous 10 | Next 10 |
Four platform presentations and two posters with data on AVROBIO’s lysosomal disorder programs to be presented AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that updat...
Avrobio Inc. ( NASDAQ: AVRO ) soared 23% amid a report that the company is exploring a possible sale after an approach from Novartis ( NVS ). A takeover for the company may be valued at more than quadruple its market price before it popped on the takeover speculation, accordin...
New compelling clinical data from first-ever Gaucher disease type 3 (GD3) patient and four Gaucher disease type 1 (GD1) patients dosed with investigational AVR-RD-02 Data from first pediatric GD3 patient, the more severe, progressive form of Gaucher disease, show biochemical correction an...
Webcast on Wednesday, Dec. 7, 2022, at 8 am ET AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will host a virtual Gaucher Disease Program Update...
AVROBIO press release ( NASDAQ: AVRO ): Q3 GAAP EPS of -$0.52 beats by $0.01 . As of September 30, 2022, AVROBIO had $116.0 million in cash and cash equivalents, as compared to $189.6 million in cash and cash equivalents as of December 31, 2021. Based on AVROBIO ...
Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis Rare pediatric disease designations received for Gaucher disease and cystinosis investigational gene therapies Comprehensive Gaucher disease program update planned for Wednesday,...
AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced senior management will be participating in a virtual panel titled “Genomic Medicines – Evolving Regulatory Environmen...
The U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation to Avrobio's ( NASDAQ: AVRO ) gene therapy AVR-RD-02 to treat Gaucher disease (GD). Gaucher disease is a rare lysosomal disorder caused by buildup of certain fatty substances in orga...
AVR-RD-02 has previously received Fast Track status from FDA, orphan drug designation in the U.S. and EU, and ILAP designation from the U.K. MHRA AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of geneti...
First five patients in Phase 1/2 trial show systemic gene therapy effect across multiple tissues evaluated, including eyes, skin, gastrointestinal mucosa and neurocognitive system AVROBIO planning to initiate company-sponsored trial in 2023 AVROBIO, Inc . (Nasdaq...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...